{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-060784","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.416574+00:00","generated_at":"2026-05-19T01:13:57.749192+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NYSE accepts Annovis Bio's plan to regain listing compliance; 18-month cure period","bullets":["Annovis received NYSE acceptance of its plan to regain compliance with minimum market capitalization and stockholders' equity standards.","NYSE granted an 18-month period from March 26, 2025, to achieve compliance; stock remains listed subject to plan adherence.","Annovis must provide quarterly progress updates to NYSE; business operations and SEC reporting unaffected."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-060784","json":"https://secwatch.observer/filing/0001104659-25-060784.json","markdown":"https://secwatch.observer/filing/0001104659-25-060784.md","text":"https://secwatch.observer/filing/0001104659-25-060784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925060784/0001104659-25-060784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925060784/tm2518347d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T01:13:57.749192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}